Cullinan Therapeutics Shares Outstanding History (CGEM)
Cullinan Therapeutics reported 60.2M shares outstanding at the end of fiscal 2025.
View full Cullinan Therapeutics company overviewCullinan Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 60.2M | 1.7M | +2.96% |
| 2024 | 2024-12-31 | 58.5M | 15.6M | +36.39% |
| 2023 | 2023-12-31 | 42.9M | −2.9M | −6.32% |
| 2022 | 2022-12-31 | 45.8M | 1.5M | +3.40% |
| 2021 | 2021-12-31 | 44.3M | 14.5M | +48.48% |
| 2020 | 2020-12-31 | 29.8M | — | — |
Cullinan Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 64.3M | 5.3M | +8.92% |
| Q1 2026 | 2026-03-31 | 61.5M | 2.8M | +4.69% |
| Q4 2025 | 2025-12-31 | 60.2M | 1.7M | +2.96% |
| Q3 2025 | 2025-09-30 | 59.1M | 935,129 | +1.61% |
| Q2 2025 | 2025-06-30 | 59.1M | 1.2M | +2.08% |
| Q1 2025 | 2025-03-31 | 58.7M | 15.6M | +36.30% |
| Q4 2024 | 2024-12-31 | 58.5M | 15.6M | +36.39% |
| Q3 2024 | 2024-09-30 | 58.1M | 15.4M | +35.97% |
| Q2 2024 | 2024-06-30 | 57.9M | 15.1M | +35.42% |
| Q1 2024 | 2024-03-31 | 43.1M | 3.7M | +9.46% |
| Q4 2023 | 2023-12-31 | 42.9M | −2.9M | −6.32% |
| Q3 2023 | 2023-09-30 | 42.8M | −3.0M | −6.52% |
| Q2 2023 | 2023-06-30 | 42.7M | −2.7M | −5.86% |
| Q1 2023 | 2023-03-31 | 39.3M | −5.3M | −11.90% |
| Q4 2022 | 2022-12-31 | 45.8M | 1.5M | +3.40% |
| Q3 2022 | 2022-09-30 | 45.7M | 2.1M | +4.77% |
| Q2 2022 | 2022-06-30 | 45.4M | 1.9M | +4.30% |
| Q1 2022 | 2022-03-31 | 44.7M | 1.1M | +2.63% |
| Q4 2021 | 2021-12-31 | 44.3M | 14.9M | +50.75% |
| Q3 2021 | 2021-09-30 | 43.7M | — | — |
| Q2 2021 | 2021-06-30 | 43.5M | — | — |
| Q1 2021 | 2021-03-31 | 43.5M | — | — |
| Q4 2020 | 2020-12-31 | 29.4M | — | — |
Cullinan Therapeutics shares outstanding trends
Over the last five reported fiscal years, Cullinan Therapeutics's shares outstanding moved from 29.8M to 60.2M, a change of 30.4M. The latest reported quarter, Q2 2026, shows 64.3M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cullinan Therapeutics filings at SEC.gov ↗